Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study

Wednesday, September 25, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the sustained effects of seralutinib on circulating biomarkers as observed in the TORREY phase 2 open-label extension study. This research highlights the drug's potential benefits for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings suggest a promising avenue for ongoing treatment strategies.
Price reaction · baseline $0.9985 (2024-09-25T18:38:00.000Z) · hit during market hours · 1 other GOSS headline(s) in the window, move may be shared
day 0 close · peak
-1.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows sustained effects on circulating biomarkers.
  • The study provides valuable insights from the TORREY phase 2 trial.
  • Positive implications for patients with PAH and PH-ILD.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib?

Seralutinib is a drug being studied for its effects on pulmonary arterial hypertension (PAH) and related conditions.

What was the focus of the TORREY study?

The TORREY study focused on the sustained effects of seralutinib on circulating biomarkers in patients.

What conditions does seralutinib target?

Seralutinib targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What are circulating biomarkers?

Circulating biomarkers are biological indicators found in the bloodstream that can reflect disease states.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib TORREY study PAH PH-ILD circulating biomarkers
Last updated: Sep 25, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →